The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

Clinical trial NCT05042336 · UNKNOWN

Trial details

NCT number: NCT05042336
Sponsor: Sichuan University
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carrelizumab Plus Lenvatinib Combined With TACE Borderline Resectable Hepatocellular Carcinoma

Start date: 2021-09-01
Primary completion: 2023-06-01
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.